After Successful COVID-19 Vaccine, Pfizer, BioNTech Come Together For mRNA-Based Shingles Vaccine

Pfizer Inc PFE and BioNTech SE BNTX have announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles.

  • The agreement marks the third collaboration between Pfizer and BioNTech in the infectious diseases field, following influenza and COVID-19 vaccine collaborations initiated in 2018 and 2020. respectively.
  • The parties will share development costs. Clinical trials are planned to start in H2 of 2022. 
  • Pfizer will have the right to commercialize the potential vaccine globally, except Germany, Turkey, and certain developing countries where BioNTech will have commercialization rights. 
  • The companies will share gross profits from the commercialization of any product.
  • Under the agreement terms, Pfizer will pay BioNTech $225 million in upfront payments, including a cash payment of $75 million and an equity investment of $150 million. 
  • BioNTech can receive future regulatory and sales milestone payments of up to $200 million. 
  • BioNTech will pay Pfizer $25 million for the company's proprietary antigen technology.
  • Price Action: BNTX shares are up 2.65% at $230.30, and PFE stock is up 1.72% at $55.47 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!